Protalix BioTherapeutics Q3 2025 Earnings Call Highlights: Revenue Growth and Regulatory Challenges

Protalix BioTherapeutics reported a 24% increase in total revenues for the first nine months of 2025, with $443.6 million. However, Q3 revenue decreased by 1% to $17.9 million. The company has a strong cash position of $29.4 million and is advancing its PRX 115 candidate for uncontrolled gout. Protalix maintains a focus on financial discipline and continues to strengthen its commercial foundation with El Fabio enzyme replacement therapy.